<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364791</url>
  </required_header>
  <id_info>
    <org_study_id>Hemopatch</org_study_id>
    <nct_id>NCT02364791</nct_id>
  </id_info>
  <brief_title>A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures</brief_title>
  <acronym>Hemopatch</acronym>
  <official_title>A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (&gt; 5 Days - PAL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether the addition of Hemopatch to standard care&#xD;
      can reduce prolonged air leaks and shorten the use of air drainage tube after surgery in&#xD;
      thoracic lung surgery patients at high risk for prolonged air leaks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of days from time of extubation to time of drainage tube removal</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of days to end of air leak</measure>
    <time_frame>up to 7 days</time_frame>
    <description>air leak measure are recorded every 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>according to Common Terminology Criteria for Adverse Events version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in quality of life</measure>
    <time_frame>baseline, one week, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days from surgical intervention to patient discharge</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thoracic Surgery Lung</condition>
  <condition>Post-operative Thoracic Air Leak</condition>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard techniques to achieve air leak control after complex thoracic surgical procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment plus hemopatch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard techniques used to achieve air leak control</intervention_name>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_label>standard treatment plus hemopatch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemopatch</intervention_name>
    <arm_group_label>standard treatment plus hemopatch</arm_group_label>
    <other_name>sealing hemostat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  High risk of prolonged air leak due to at least one of the following reasons:&#xD;
&#xD;
               -  Preoperative FEV1&lt;80%&#xD;
&#xD;
               -  DLco &lt; 80%&#xD;
&#xD;
               -  LVRS (lung volume reduction surgery o pneumoplastica riduttiva)&#xD;
&#xD;
               -  Anticipation of intraoperative adhesions (ie, redo surgery)&#xD;
&#xD;
               -  Previous induction chemotherapy for locally advanced NSCLC&#xD;
&#xD;
               -  Chronic steroid use&#xD;
&#xD;
               -  Pleural mesothelioma&#xD;
&#xD;
          -  Candidate to one of the following major thoracic surgical intervention:&#xD;
&#xD;
               -  Decortication&#xD;
&#xD;
               -  Reintervention on the same side of the previous intervention&#xD;
&#xD;
               -  Segmentectomy&#xD;
&#xD;
               -  Lobectomy with incomplete fissures on CT scan&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Evidence of confusion or disorientation, or history of major psychiatric illness that&#xD;
             may impair the patient's understanding of the Informed Consent Form or their ability&#xD;
             to comply with study requirements&#xD;
&#xD;
          -  Any unstable systemic disease (including active infections, any significant hepatic,&#xD;
             renal or cardiovascular disease), metabolic dysfunction, physical examination finding,&#xD;
             or clinical laboratory finding that contraindicates or prevents or the execution of&#xD;
             surgery&#xD;
&#xD;
          -  Known hypersensitivity to bovine proteins or brilliant blue (FD&amp;C Blue No.1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Rocco, MD, FRCSEd</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - Fondazione &quot;G.Pascale&quot;, IRCCS</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary resection</keyword>
  <keyword>chest tube</keyword>
  <keyword>segmentectomy</keyword>
  <keyword>lobectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

